Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2025-02-28 00:00:00 ET · period of report 2025-02-26 · accession 0000875320-25-000127 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-02-28 | 2025-02-26 | VRTX | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off | F - Tax | $479.61 | -2,482 | 22.0K | -10% | -$1.19M | |
| 2025-02-28 | 2025-02-27 | VRTX | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off | S - Sale | $475.34 | -2,650 | 19.4K | -12% | -$1.26M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-26 | F | D | 2,482 | $479.61 | 22,002 | D | — | — | |
| 2 | Common | Common Stock | 2025-02-27 | S | D | 2,650 | $475.34 | 19,352 | D | — | — |